GeneOne Life Science Inc - Asset Resilience Ratio
GeneOne Life Science Inc (011000) has an Asset Resilience Ratio of 0.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GeneOne Life Science Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how GeneOne Life Science Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of GeneOne Life Science Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down GeneOne Life Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GeneOne Life Science Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩415.88 Million | 0.35% |
| Total Liquid Assets | ₩415.88 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: GeneOne Life Science Inc maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GeneOne Life Science Inc Industry Peers by Asset Resilience Ratio
Compare GeneOne Life Science Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for GeneOne Life Science Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for GeneOne Life Science Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.35% | ₩415.88 Million ≈ $281.83K |
₩119.21 Billion ≈ $80.78 Million |
-0.03pp |
| 2024-12-31 | 0.37% | ₩566.19 Million ≈ $383.70K |
₩151.33 Billion ≈ $102.56 Million |
-0.21pp |
| 2023-12-31 | 0.58% | ₩877.39 Million ≈ $594.60K |
₩151.01 Billion ≈ $102.34 Million |
-13.93pp |
| 2022-12-31 | 14.51% | ₩32.34 Billion ≈ $21.92 Million |
₩222.87 Billion ≈ $151.03 Million |
-19.59pp |
| 2021-12-31 | 34.11% | ₩85.09 Billion ≈ $57.67 Million |
₩249.50 Billion ≈ $169.08 Million |
+13.54pp |
| 2020-12-31 | 20.57% | ₩28.09 Billion ≈ $19.03 Million |
₩136.57 Billion ≈ $92.55 Million |
+19.17pp |
| 2019-12-31 | 1.39% | ₩711.93 Million ≈ $482.47K |
₩51.15 Billion ≈ $34.67 Million |
-27.64pp |
| 2018-12-31 | 29.04% | ₩14.31 Billion ≈ $9.70 Million |
₩49.30 Billion ≈ $33.41 Million |
+5.75pp |
| 2017-12-31 | 23.29% | ₩10.63 Billion ≈ $7.20 Million |
₩45.63 Billion ≈ $30.93 Million |
-3.45pp |
| 2016-12-31 | 26.74% | ₩17.56 Billion ≈ $11.90 Million |
₩65.66 Billion ≈ $44.50 Million |
+3.08pp |
| 2015-12-31 | 23.66% | ₩11.28 Billion ≈ $7.65 Million |
₩47.69 Billion ≈ $32.32 Million |
-5.63pp |
| 2014-12-31 | 29.29% | ₩11.94 Billion ≈ $8.09 Million |
₩40.77 Billion ≈ $27.63 Million |
+20.13pp |
| 2013-12-31 | 9.17% | ₩2.92 Billion ≈ $1.98 Million |
₩31.82 Billion ≈ $21.56 Million |
-23.00pp |
| 2012-12-31 | 32.16% | ₩12.85 Billion ≈ $8.71 Million |
₩39.96 Billion ≈ $27.08 Million |
+14.48pp |
| 2011-12-31 | 17.68% | ₩7.15 Billion ≈ $4.85 Million |
₩40.46 Billion ≈ $27.42 Million |
+11.04pp |
| 2010-12-31 | 6.65% | ₩2.66 Billion ≈ $1.80 Million |
₩40.05 Billion ≈ $27.14 Million |
-27.69pp |
| 2009-12-31 | 34.33% | ₩20.27 Billion ≈ $13.74 Million |
₩59.04 Billion ≈ $40.01 Million |
-- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more